Applied Therapeutics has claimed a victory in its phase 3 SORD fight, setting up plans to talk to the FDA about filing for approval, although a flip-flopping stock price points to questions over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback